BR112022015104A2 - Método para melhorar a distribuição e estender a meia-vida plasmática de uma composição de roflumilaste e uso de uma composição - Google Patents

Método para melhorar a distribuição e estender a meia-vida plasmática de uma composição de roflumilaste e uso de uma composição

Info

Publication number
BR112022015104A2
BR112022015104A2 BR112022015104A BR112022015104A BR112022015104A2 BR 112022015104 A2 BR112022015104 A2 BR 112022015104A2 BR 112022015104 A BR112022015104 A BR 112022015104A BR 112022015104 A BR112022015104 A BR 112022015104A BR 112022015104 A2 BR112022015104 A2 BR 112022015104A2
Authority
BR
Brazil
Prior art keywords
composition
roflumilast
life
extend
distribution
Prior art date
Application number
BR112022015104A
Other languages
English (en)
Inventor
W Osborne David
Chaudhuri Bhaskar
W Thurston Archie
Original Assignee
Arcutis Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/778,845 external-priority patent/US11129818B2/en
Application filed by Arcutis Biotherapeutics Inc filed Critical Arcutis Biotherapeutics Inc
Publication of BR112022015104A2 publication Critical patent/BR112022015104A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

MÉTODO PARA MELHORAR A DISTRIBUIÇÃO E ESTENDER A MEIA-VIDA PLASMÁTICA DE UMA COMPOSIÇÃO DE ROFLUMILASTE E USO DE UMA COMPOSIÇÃO. A presente invenção é direcionada a métodos para melhorar o resultado terapêutico do tratamento com roflumilaste. O resultado terapêutico é melhorado por meio da distribuição consistente e/ou uma meia-vida plasmática mais longa de uma composição de roflumilaste administrada por via tópica. A composição de roflumilaste inclui preferencialmente fosfato de dicetila, fosfato de ceteth-10, dietilenoglicol monoetil éter e/ou hexilenoglicol.
BR112022015104A 2020-01-31 2021-01-29 Método para melhorar a distribuição e estender a meia-vida plasmática de uma composição de roflumilaste e uso de uma composição BR112022015104A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/778,845 US11129818B2 (en) 2017-06-07 2020-01-31 Topical roflumilast formulation having improved delivery and plasma half life
PCT/US2021/015740 WO2021155173A1 (en) 2020-01-31 2021-01-29 Topical roflumilast formulation having improved delivery and plasma half-life

Publications (1)

Publication Number Publication Date
BR112022015104A2 true BR112022015104A2 (pt) 2022-09-27

Family

ID=74759470

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022015104A BR112022015104A2 (pt) 2020-01-31 2021-01-29 Método para melhorar a distribuição e estender a meia-vida plasmática de uma composição de roflumilaste e uso de uma composição

Country Status (10)

Country Link
EP (1) EP4096630A1 (pt)
JP (1) JP2023513092A (pt)
KR (1) KR20220134617A (pt)
CN (1) CN115551478A (pt)
AU (1) AU2021214399A1 (pt)
BR (1) BR112022015104A2 (pt)
CA (1) CA3166300A1 (pt)
IL (1) IL295172A (pt)
MX (1) MX2022009399A (pt)
WO (1) WO2021155173A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240108609A1 (en) * 2022-09-15 2024-04-04 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2176252T3 (es) 1993-07-02 2002-12-01 Altana Pharma Ag Benzamidas sustituidas con fluoro-alcoxi y su utilizacion como agentes inhibidores de fosfodiesterasas de nucleotidos ciclicos.
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
NZ553731A (en) 2002-05-28 2007-07-27 Altana Pharma Ag Topically applicable pharmaceutical preparation of roflumilast and liquid paraffin
DE102004046235A1 (de) 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
US20200155524A1 (en) * 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US9895359B1 (en) * 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US11534493B2 (en) * 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
AU2019281888B2 (en) * 2018-06-04 2024-05-02 Arcutis Biotherapeutics, Inc. Method and formulation for improving roflumilast skin penetration lag time

Also Published As

Publication number Publication date
EP4096630A1 (en) 2022-12-07
CA3166300A1 (en) 2021-08-05
CN115551478A (zh) 2022-12-30
JP2023513092A (ja) 2023-03-30
IL295172A (en) 2022-09-01
WO2021155173A1 (en) 2021-08-05
MX2022009399A (es) 2022-09-19
AU2021214399A1 (en) 2022-08-25
KR20220134617A (ko) 2022-10-05

Similar Documents

Publication Publication Date Title
CL2023002090A1 (es) Inhibidores de kras tricíclicos fusionados
BR112018001640A2 (pt) combinação de antagonista da pd-1 com um inibidor de egfr
BR112022009571A2 (pt) Uso de inibidor de fak na preparação de um fármaco para tratar tumores que têm mutação nras
AR110419A1 (es) Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles
BR112023015067A2 (pt) Composto de quinazolina para induzir a degradação de proteína kras g12d mutante
MX2023004032A (es) Terapias inmuno-oncologicas con conjugados de il-2.
BR112022015104A2 (pt) Método para melhorar a distribuição e estender a meia-vida plasmática de uma composição de roflumilaste e uso de uma composição
BR112023002453A2 (pt) Composições de agente de via de estresse de replicação e métodos para tratar câncer
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
MX2021011230A (es) Administracion subcutanea de nanoparticulas que comprenden un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y albumina para tratamiento de enfermedades.
MX2022006176A (es) Terapia combinada que comprende un inhibidor de alk2 y un inhibidor de jak2.
MX2022000430A (es) Administracion de agonista de sting e inhibidores de puntos de control.
MX2022015554A (es) Moduladores de molecula peque?a de interleucina 17 (il-17).
ECSP22098041A (es) Inhibidores alostéricos de egfr y métodos de uso de estos
MX2021007565A (es) Composiciones y metodos para la terapia contra el cancer.
CO2023014650A2 (es) Dosificación y administración de l-asparaginasa recombinante
MX2023006370A (es) Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.
BRPI1008000A2 (pt) composto, hidrobrometo, hidrocloreto, metanossulfonato, etano-1, 2-dissulfonato, inibidor de hsp90, agente para inibir a atividade de atpase de hsp90, agente para inibir a ligação de hsp90 em atp, medicamento, agente anticâncer, composição farmacêutica, método para tratar câncer, e, uso de um composto.
BR112022012081A2 (pt) Método para tratar câncer, kit, e, uso de uma combinação terapêutica
CL2021001638A1 (es) Tratamiento del cáncer con docetaxel controlando los niveles plasmáticos máximos
EP4356966A3 (en) Dosing regimens associated with extended release paliperidone injectable formulations
BR112022026558A2 (pt) Novo composto e composição farmacêutica para prevenir ou tratar câncer resistente que compreende o mesmo
JOP20220104A1 (ar) نظام تجريع لعوامل مضادة لـ dll3
BR112023002883A2 (pt) Conjunto de composições para tratamento bucal anticárie
MX2022006155A (es) Terapias anticancerosas con anamicina liposomica orientadas al pulmon.